Cargando…

Increased expression of EHF contributes to thyroid tumorigenesis through transcriptionally regulating HER2 and HER3

E26 transformation-specific (ETS) transcription factor EHF plays a tumor suppressor role in prostate cancer and esophageal squamous cell carcinoma (ESCC), whereas it is overexpressed and may act as an oncogene in ovarian and mammary cancers. However, its biological role in thyroid cancer remains tot...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lv, Yanyan, Sui, Fang, Ma, Jingjing, Ren, Xiaojuan, Yang, Qi, Zhang, Yanfang, Guan, Haixia, Shi, Bingyin, Hou, Peng, Ji, Meiju
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5295405/ https://www.ncbi.nlm.nih.gov/pubmed/27517321 http://dx.doi.org/10.18632/oncotarget.11154

Ejemplares similares

Increased expression of EHF via gene amplification contributes to the activation of HER family signaling and associates with poor survival in gastric cancer
por: Shi, Jing, et al.
Publicado: (2016)

Metallothionein 1G functions as a tumor suppressor in thyroid cancer through modulating the PI3K/Akt signaling pathway
por: Fu, Jiao, et al.
Publicado: (2013)

Sulforaphane inhibits thyroid cancer cell growth and invasiveness through the reactive oxygen species-dependent pathway
por: Wang, Liping, et al.
Publicado: (2015)

PAX3 is a novel tumor suppressor by regulating the activities of major signaling pathways and transcription factor FOXO3a in thyroid cancer
por: Liu, Wei, et al.
Publicado: (2016)

Highly frequent promoter methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC)
por: Ji, Meiju, et al.
Publicado: (2011)

Increased autophagy blocks HER2-mediated breast tumorigenesis
por: Vega-Rubín-de-Celis, Silvia, et al.
Publicado: (2018)

HER2 inhibition increases non-muscle myosin IIA to promote tumorigenesis in HER2+ breast cancers
por: Alanazi, Samar M., et al.
Publicado: (2023)

Dmp1α Inhibits HER2/neu-Induced Mammary Tumorigenesis
por: Fry, Elizabeth A., et al.
Publicado: (2013)

Overview of the EHF Project
por: Bradamante, Franco
Publicado: (1988)

Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER‐targeted therapy in HER2 amplification‐positive and HER2 mutation‐positive amplification‐negative patients
por: Liu, Binliang, et al.
Publicado: (2022)

HER2/Neu tumorigenesis and metastasis is regulated by E2F activator transcription factors
por: Andrechek, Eran R.
Publicado: (2013)

An intensity staged approach of EHF
por: Blüm, P
Publicado: (1987)

Energy upgrade of the EHF SCL
por: Vretenar, Maurizio, et al.
Publicado: (1987)

Exitation of the EHF dipole magniets
por: European Hadron Facility Study Group
Publicado: (1987)

Linc01638 Promotes Tumorigenesis in HER2+ Breast Cancer
por: Liu, Peng, et al.
Publicado: (2019)

c-Myc is Required for BRAF(V600E)-Induced Epigenetic Silencing by H3K27me3 in Tumorigenesis
por: Qu, Yiping, et al.
Publicado: (2017)

A novel HER2 gene body enhancer contributes to HER2 expression
por: Liu, Q, et al.
Publicado: (2018)

Increased expression of NAF1 contributes to malignant phenotypes of glioma cells through promoting protein synthesis and associates with poor patient survival
por: Wei, Jing, et al.
Publicado: (2019)

Design Principles for EHF Magnet Circuits
por: Bothe, Werner
Publicado: (1987)

Hints: for a single-sychrotron EHF
por: Schönauer, Horst Otto
Publicado: (1987)

A nonlinear analysis of the EHF booster
por: Colton, Eugene, et al.
Publicado: (1987)

One snake in EHF main ring
por: Pisent, A
Publicado: (1987)

Summary of the 14th EHF Workshop
por: Bradamante, Franco
Publicado: (1989)

Polarization capabilities of EHF pre-booster
por: Galluccio, Francesca, et al.
Publicado: (1989)

Summary of the 15th EHF Workshop
por: Bradamante, Franco
Publicado: (1989)

Conceptual design for the EHF-LEGNARO project
por: Ruggiero, A G
Publicado: (1989)

Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer
por: Yi, Zongbi, et al.
Publicado: (2020)

RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer
por: Sanz-Moreno, Adrián, et al.
Publicado: (2021)

HER kinase inhibition in patients with HER2- and HER3-mutant cancers
por: Hyman, David M., et al.
Publicado: (2018)

HER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancer
por: Chandran, Vineesh Indira, et al.
Publicado: (2015)

Pre-booster for alpi-EHF-combined projects
por: Bothe, W
Publicado: (1989)

The TRIUMF KAON factory, EHF-89-19
por: Craddock, M K
Publicado: (1989)

A new RFQ injector for the EHF LINAC
por: Deitinghof, H, et al.
Publicado: (1989)

Strategies for longitudinal painting in the EHF booster at injection
por: Gianfelice, E, et al.
Publicado: (1988)

Proposal for a European Hadron Facility (EHF)
por: Bradamante, Franco, et al.
Publicado: (1987)

European Hadron Facility (EHF): letter of intent
por: Johannes Gutenberg-Universitaet. Mainz. Institut fuer Physik
Publicado: (1986)

Strategies for longitudinal painting in the EHF booster at injection
por: Gianfelice-Wendt, E, et al.
Publicado: (1989)

ELF3, ELF5, EHF and SPDEF Transcription Factors in Tissue Homeostasis and Cancer
por: Luk, Ian Y., et al.
Publicado: (2018)

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
por: Sassen, Andrea, et al.
Publicado: (2008)

Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors
por: Floros, Konstantinos V., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_j7id2bqjf3u2k7g06cg9rq6oqs